Diagnostic and treatment algorithms of ulcerative colitis in Ukraine

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 550-554

  Skrypnyk, I N ^a  

^a UKRAINIAN MEDICAL STOMATOLOGICAL ACADEMY   (Ukraine)

Author keywords

Diagnostic algorithms; Treatment algorithms; Ulcerative colitis, diagnostics; Ulcerative colitis, pathogenesis; Ulcerative colitis, Ukraine

Indexed keywords

ADALIMUMAB; BUDESONIDE; CERTOLIZUMAB PEGOL; FUCOSE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MESALAZINE; NATALIZUMAB; REBAMIPIDE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

COLON; COLONOSCOPY; CONVALESCENCE; CYTOSTASIS; DRUG EFFICACY; HUMAN; INFLAMMATION; LACTOBACILLUS; MUCOSA; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIDEOENDOSCOPY;

COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; HUMANS; UKRAINE;

EID: 70449487657     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233296     Document Type: Review

References (28)

1. Rogala L, Miller N, Graf LA, Rawsthorne P, Clara I, Walker JR, Lix L, Ediger JP, McPhail C, Bernstein CN: Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to healthcare in inflammatory bowel disease. Inflamm Bowel Dis 2008; 23: 98-101.
2. Dorofeev AE: Diagnostic and Treatment of the Gastroenterological Diseases. Donetsk, Nord-Press, 2009.
3. Scholmerich J: Ulcerative Colitis and Crohn's Disease. Abstr Falk Workshop on Digestive Diseases: State of the Art and Daily Practice, Santiago de Chile, 2008, pp 15-16.
4. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cornes J: Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001; 96: 2113-2116. (Pubitemid 32660906)
5. Cornes J, Carbonnel F, Beaugerie L, Blain A, Reijasse D, Gendre JP: Effect of appendicectomy on the course of ulcerative colitis. Gut 2002; 51: 803-807.
6. Schwab M, Schaffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Scholmerich J, Gregor M, Walker S, Carcorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26-33.
7. Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-1640.
8. Tibble JA, Bjarnason I: Fecal calprotein as an index of intestinal inflammation. Drugs Today 2001; 37: 85-96.
9. Mikhaylova Y, Pimanov SI, Voropayev Y, Timashova VR: The fecal marker of ulcerative colitis. Rus J Gastroenterol Hepatol Coloproctol 2007; 17: 60-63.
10. Farup PG, Hilterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. IBD 2001; 7: 237-242.
11. Kruis W: The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dosefinding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 36-43.
12. Faubion WA, Loftus RV, Harmessen WS: The natural history of corticosteroid therapy for inflammatory bowel disease: a population- based study. Gastroenterology 2001; 121: 255-260.
13. Kolkman JJ, Molmann HW, Molmann AC: Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today 2004; 40: 589-601.
14. Hawthorne AB, Logan R NA, Hawkey CJ: Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992; 305: 20-22.
15. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P: Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-765.
16. Probert C, Hearing S, Schreiber S: Infliximab in moderately severe glucocorticoidresistant ulcerative colitis: a randomized controlled trial. Gut 2003; 52: 998-1002.
17. Rutgeerts P, Sandborn WJ, Feagan BG: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476. (Pubitemid 41770166)
18. Miyata M, Satoh M, Kasugai K, Kakumi S, Mori T, Onishi M: Rebamipide enema versus 5-aminosalicylic acid enema for distal ulcerative colitis: a randomized controlled trial. Gut 2006; 55(suppl 5):A128.
19. Ogata H, Kamada N, Inoue N, Matsui T, Hibi T: A randomized, multicentre pilot study comparing mesalazine enemas and rebamipide enemas for active ulcerative colitis. Gut 2006; 55(suppl 5):A129.
20. Kobayashi T, Zinchuk VS, Garcia del Saz E: Suppressive effect of rebamipide, an antiulcer agent, against activation of human neutrophils exposed to formyl-methionylleucyl- phenylalanine. Histol Histopathol 2000; 15: 1067-1076.
21. Masamure A, Yoshida M, Sakai Y, et al: Rebamipide inhibits ceramide-induced interleukin- 8 production in Kato III human gastric cancer cells. J Pharmacol Exp Ther 2001; 298: 485-494.
22. Zocco MA, Zileri dal Verme L, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A: Efficacy of lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574.
23. Akcan A, Kucuk C, Sozuer E, Esel D, Akyildiz H, Akgun H, Muhtaroglu S, Aritas Y: Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J Gastroenterol 2008; 14: 918-924. (Pubitemid 351325032)
24. Pankov R, Markovska T, Antonov P: Influence of membrane phospholipids composition and structural organization on spontaneous lipid transfer between membranes. Gen Physiol Biophys 2006; 25: 313-324.
25. Kingsley M: Effects of phophatidylserine supplementation on exercising humans. Sports Med 2006; 36: 557-669.
26. Skrypnyk I: Optimization of the treatment of the alcoholic liver disease patients in association with atherosclerosis. Gut 2007; 56(suppl 3):A269.
27. Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrugger R, Porro GB, Drossman DA: Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol 2003; 38: 1031-1038.
28. Van Assche G: Communication and beliefs of quality of life and mucosal healing treatment goal in everyday practice: results of a large pan-European survey of physicians treating inflammatory bowel disease. Gut 2007; 56(suppl 3):A162.